Chemical Component Summary

Identifiers [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
(1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid
Formula C5 H10 N2 O7 P2
Molecular Weight 272.09 g/mol
Type non-polymer
Isomeric SMILES OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O
InChI InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)

Chemical Details

Formal Charge 0
Atom Count 26
Chiral Atom Count 0
Chiral Atoms
Bond Count 26
Aromatic Bond Count 5

Drug Info: DrugBank

DrugBank ID DB00399   (Stereoisomeric match)
Name Zoledronate
Groups approved
Description Zoledronate (zoledronic acid, marketed by Novartis under the trade names Zometa and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronate is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.
  • (1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
  • (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
  • Reclast
  • ZOL
  • Zoledronic acid
Brand Names
  • Aclasta
  • Act Zoledronic Acid
  • Act Zoledronic Acid Concentrate
  • PMS-zoledronic Acid
  • Reclast
  • Taro-zoledronic Acid
  • Taro-zoledronic Acid Concentrate
  • Val-zoledronic Acid
  • Zoledronic Acid
  • Zoledronic Acid - A
  • Zoledronic Acid - Z
  • Zoledronic Acid Concentrate
  • Zoledronic Acid Concentrate for Injection
  • Zoledronic Acid Injection
  • Zoledronic Acid for Injection
  • Zoledronic Acid for Injection Concentrate
  • Zometa
  • Zometa Concentrate
  • Zometa Lyophilized Powder
Affected Organism Humans and other mammals
Indication For the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget’s Disease.
Pharmacology Zoledronate is a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronate is used to prevent osteoporosis and skeletal fractures, particularly in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia, particularly hypercalcemia of malignancy. It can also be helpful for treating pain from bone metastases.
Mechanism of action The action of zoledronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Zoledronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates such as zoledronate appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Route of administration
  • intravenous
  • Bone Density Conservation Agents
  • Antihypocalcemic Agents
  • Antiresorptives
  • Bisphosphonates
ATC-Code M05BA08
AHFS-Code 92:00.00
CAS number 118072-93-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682